Cargando…

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

OBJECTIVE: To investigate the relationship between Excision repair cross-complementation 1 (ERCC1) expression, clinicopathological features, and breast cancer prognosis in patients treated with trastuzumab. Further, we aim to explore the immune status of ERCC1 in breast cancer. METHODS: The data wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yilun, Liao, Xiaomei, Ma, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631216/ https://www.ncbi.nlm.nih.gov/pubmed/36338712 http://dx.doi.org/10.3389/fonc.2022.955719

Ejemplares similares

Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy
por: Jiang, Hong, et al.
Publicado: (2019)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

Associations of individual and joint expressions of ERCC6 and ERCC8 with clinicopathological parameters and prognosis of gastric cancer
por: Chen, Jing, et al.
Publicado: (2021)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Polymorphisms in ERCC4 and ERCC5 and risk of cancers: Systematic research synopsis, meta-analysis, and epidemiological evidence
por: Zuo, Chunjian, et al.
Publicado: (2022)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

Correlation of ERCC5 polymorphisms and linkage disequilibrium associated with overall survival and clinical outcome to chemotherapy in breast cancer
por: Khan, Iqra, et al.
Publicado: (2023)

Association Between ERCC1 rs3212986 and ERCC2/XPD rs1799793 and OS in Patients With Advanced Esophageal Cancer
por: Boldrin, Elisa, et al.
Publicado: (2019)

Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma
por: Qin, Zhongqiang, et al.
Publicado: (2023)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

Establishment and validation of a ferroptosis-related signature predicting prognosis and immunotherapy effect in colon cancer
por: Li, Zhufeng, et al.
Publicado: (2023)

Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer
por: Wang, Yue, et al.
Publicado: (2022)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
por: Liu, Chang-Gen, et al.
Publicado: (2023)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Comprehensive analysis of the expression and prognosis for RAI2: A promising biomarker in breast cancer
por: Jiao, Ying, et al.
Publicado: (2023)

Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers
por: Cai, Yuan, et al.
Publicado: (2022)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma
por: Liao, Xiaoli, et al.
Publicado: (2020)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
por: Zhang, Yu, et al.
Publicado: (2022)

The value of metabolic LncRNAs in predicting prognosis and immunotherapy efficacy of gastric cancer
por: Du, Peizhun, et al.
Publicado: (2023)

Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy
por: Ding, Jian, et al.
Publicado: (2022)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Relationship between telomere length and the prognosis of breast cancer based on estrogen receptor status: A Mendelian randomization study
por: Li, Yilun, et al.
Publicado: (2022)

ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer
por: Choueiri, Michel B., et al.
Publicado: (2015)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
por: Nie, Guilin, et al.
Publicado: (2023)

Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Hu, Xiaoyi, et al.
Publicado: (2020)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer
por: Liu, Zhifei, et al.
Publicado: (2022)

Case Report: Lung adenocarcinoma associated with germline ERCC2 frameshift mutation
por: Liu, Lili, et al.
Publicado: (2023)

High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy
por: Zhang, Huikun, et al.
Publicado: (2021)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h9cjtr6b5c0tei87vpkcitit48